Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCED-2: TARA-002 in High-Grade Non-Muscle Invasive Bladder Cancer
jRCT2031250084Phase 2Recruiting
- Sponsor
- Protara Therapeutics
- Start
- Oct 2025
- Modality
- Cell Therapies
01
Overview
Phase 2, open-label trial of TARA-002 in bladder cancer and Bladder cancer in situ (CIS) (2 cohorts), sponsored by Protara Therapeutics. Primary endpoint: Incidence of high-grade complete response at any time. Started Oct 2025; status: recruiting.
02
Drugs
TARA-002
03
Conditions
bladder cancerBladder cancer in situ (CIS)
Beyond the preview
Go deeper on jRCT2031250084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250084.